N-terminal truncation of an isolated human IgG1 CH2 domain significantly increases its stability and aggregation resistance

Molecular Pharmaceutics

Volumn 10, Issue 7, 2013, Pages 2642-2652

  Gong, Rui ^a,b   Wang, Yanping ^b,c   Ying, Tianlei ^b   Feng, Yang ^b   Streaker, Emily ^b,c   Prabakaran, Ponraj ^b,c   Dimitrov, Dimiter S ^b  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SAIC FREDERICK INC   (United States)

Author keywords

aggregation resistance; CH2 domain; Fc; IgG; stability

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN G; THIOFLAVINE;

ARTICLE; FLOW CYTOMETRY; FLUORESCENCE; LIGHT SCATTERING; PH; PRIORITY JOURNAL; TURBIDITY;

DRUG STABILITY; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SERUM ALBUMIN; THIAZOLES;

EID: 84879721351     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400075f     Document Type: Article

References (46)

1. Waldmann, T. A. Immunotherapy: past, present and future Nat. Med. 2003, 9 (3) 269-77
2. Casadevall, A.; Dadachova, E.; Pirofski, L. A. Passive antibody therapy for infectious diseases Nat. Rev. Microbiol. 2004, 2 (9) 695-703
3. Schrama, D.; Reisfeld, R. A.; Becker, J. C. Antibody targeted drugs as cancer therapeutics Nat. Rev. Drug Discovery 2006, 5 (2) 147-59
4. Carter, P. J. Potent antibody therapeutics by design Nat. Rev. Immunol. 2006, 6 (5) 343-57
5. Dimitrov, D. S.; Marks, J. D. Therapeutic antibodies: current state and future trends - is a paradigm change coming soon? Methods Mol. Biol. 2009, 525, 1-27
6. Dimitrov, D. S. Therapeutic antibodies, vaccines and antibodyomes mAbs 2010, 2 (3) 347-56
7. Zhu, Z.; Prabakaran, P.; Chen, W.; Broder, C. C.; Gong, R.; Dimitrov, D. S. Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1 Virol. Sin. 2013, 28 (2) 71-80
8. Dimitrov, D. S. Engineered CH2 domains (nanoantibodies) mAbs 2009, 1 (1) 26-8
9. Nuttall, S. D.; Walsh, R. B. Display scaffolds: protein engineering for novel therapeutics Curr. Opin. Pharmacol. 2008, 8 (5) 609-15
10. Roopenian, D. C.; Akilesh, S. FcRn: the neonatal Fc receptor comes of age Nat. Rev. Immunol. 2007, 7 (9) 715-25
11. Prabakaran, P.; Vu, B. K.; Gan, J.; Feng, Y.; Dimitrov, D. S.; Ji, X. Structure of an isolated unglycosylated antibody C(H)2 domain Acta Crystallogr., D 2008, 64 (Pt 10) 1062-7
12. Gong, R.; Chen, W.; Dimitrov, D. S. Candidate antibody-based therapeutics against HIV-1 BioDrugs 2012, 26 (3) 143-62
13. Xiao, X.; Feng, Y.; Vu, B. K.; Ishima, R.; Dimitrov, D. S. A large library based on a novel (CH2) scaffold: identification of HIV-1 inhibitors Biochem. Biophys. Res. Commun. 2009, 387 (2) 387-92
14. Saphire, E. O.; Parren, P. W.; Pantophlet, R.; Zwick, M. B.; Morris, G. M.; Rudd, P. M. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design Science 2001, 293 (5532) 1155-9
15. Sondermann, P.; Huber, R.; Oosthuizen, V.; Jacob, U. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex Nature 2000, 406 (6793) 267-73
16. Lefranc, M. P.; Pommie, C.; Kaas, Q.; Duprat, E.; Bosc, N.; Guiraudou, D. IMGT unique numbering for immunoglobulin and T cell receptor constant domains and Ig superfamily C-like domains Develop. Comp. Immunol. 2005, 29 (3) 185-203
17. Gong, R.; Vu, B. K.; Feng, Y.; Prieto, D. A.; Dyba, M. A.; Walsh, J. D. Engineered human antibody constant domains with increased stability J. Biol. Chem. 2009, 284 (21) 14203-10
18. Gong, R.; Chen, W.; Dimitrov, D. S. Expression, purification, and characterization of engineered antibody CH2 and VH domains Methods Mol. Biol. 2012, 899, 85-102
19. Chao, G.; Lau, W. L.; Hackel, B. J.; Sazinsky, S. L.; Lippow, S. M.; Wittrup, K. D. Isolating and engineering human antibodies using yeast surface display Nat. Protoc. 2006, 1 (2) 755-68
20. Gong, R.; Wang, Y.; Feng, Y.; Zhao, Q.; Dimitrov, D. S. Shortened engineered human antibody CH2 domains: increased stability and binding to the human neonatal Fc receptor J. Biol. Chem. 2011, 286 (31) 27288-93
21. Feng, Y.; Gong, R.; Dimitrov, D. S. Design, expression and characterization of a soluble single-chain functional human neonatal Fc receptor Protein. Expr. Purif. 2011, 79 (1) 66-71
22. Arnold, K.; Bordoli, L.; Kopp, J.; Schwede, T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling Bioinformatics 2006, 22 (2) 195-201
23. Ramsland, P. A.; Farrugia, W.; Bradford, T. M.; Sardjono, C. T.; Esparon, S.; Trist, H. M. Structural basis for Fc gammaRIIa recognition of human IgG and formation of inflammatory signaling complexes J. Immunol. 2011, 187 (6) 3208-17
24. Fernandez-Escamilla, A. M.; Rousseau, F.; Schymkowitz, J.; Serrano, L. Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins Nat. Biotechnol. 2004, 22 (10) 1302-6
25. Fraczkiewicz, R.; Braun, W. Exact and efficient analytical calculation of the accessible surface areas and their gradients for macromolecules J. Comput. Chem. 1998, 19 (3) 319-33
26. The PyMOL Molecular Graphics System, Version 1.2 ed.; Schrödinger, LLC.
27. Kayser, V.; Chennamsetty, N.; Voynov, V.; Helk, B.; Trout, B. L. Conformational stability and aggregation of therapeutic monoclonal antibodies studied with ANS and Thioflavin T binding mAbs 2011, 3 (4) 408-11
28. Edelman, G. M.; Cunningham, B. A.; Gall, W. E.; Gottlieb, P. D.; Rutishauser, U.; Waxdal, M. J. The covalent structure of an entire gammaG immunoglobulin molecule Proc. Natl. Acad. Sci. U. S. A. 1969, 63 (1) 78-85
29. Holliger, P.; Hudson, P. J. Engineered antibody fragments and the rise of single domains Nat. Biotechnol. 2005, 23 (9) 1126-36
30. Ewert, S.; Huber, T.; Honegger, A.; Pluckthun, A. Biophysical properties of human antibody variable domains J. Mol. Biol. 2003, 325 (3) 531-53
31. Barthelemy, P. A.; Raab, H.; Appleton, B. A.; Bond, C. J.; Wu, P.; Wiesmann, C. Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains J. Biol. Chem. 2008, 283 (6) 3639-54
32. Tanha, J.; Nguyen, T. D.; Ng, A.; Ryan, S.; Ni, F.; Mackenzie, R. Improving solubility and refolding efficiency of human V(H)s by a novel mutational approach Protein Eng. Des. Sel. 2006, 19 (11) 503-9
33. Arbabi-Ghahroudi, M.; To, R.; Gaudette, N.; Hirama, T.; Ding, W.; MacKenzie, R. Aggregation-resistant VHs selected by in vitro evolution tend to have disulfide-bonded loops and acidic isoelectric points Protein Eng. Des. Sel. 2009, 22 (2) 59-66
34. Perchiacca, J. M.; Bhattacharya, M.; Tessier, P. M. Mutational analysis of domain antibodies reveals aggregation hotspots within and near the complementarity determining regions Proteins 2011, 79 (9) 2637-47
35. Perchiacca, J. M.; Ladiwala, A. R.; Bhattacharya, M.; Tessier, P. M. Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions Protein Eng. Des. Sel. 2012, 25 (10) 591-601
36. Latypov, R. F.; Hogan, S.; Lau, H.; Gadgil, H.; Liu, D. Elucidation of acid-induced unfolding and aggregation of human immunoglobulin IgG1 and IgG2 Fc J. Biol. Chem. 2012, 287 (2) 1381-96
37. Chennamsetty, N.; Voynov, V.; Kayser, V.; Helk, B.; Trout, B. L. Design of therapeutic proteins with enhanced stability Proc. Natl. Acad. Sci. U.S.A. 2009, 106 (29) 11937-42
38. Esposito, G.; Michelutti, R.; Verdone, G.; Viglino, P.; Hernandez, H.; Robinson, C. V. Removal of the N-terminal hexapeptide from human beta2-microglobulin facilitates protein aggregation and fibril formation Protein Sci. 2000, 9 (5) 831-45
39. Hackel, B. J.; Kapila, A.; Wittrup, K. D. Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling J. Mol. Biol. 2008, 381 (5) 1238-52
40. Feige, M. J.; Walter, S.; Buchner, J. Folding mechanism of the CH2 antibody domain J. Mol. Biol. 2004, 344 (1) 107-18
41. Richardson, J. S.; Richardson, D. C. Natural beta-sheet proteins use negative design to avoid edge-to-edge aggregation Proc. Natl. Acad. Sci. U.S.A. 2002, 99 (5) 2754-9
42. Buck, P. M.; Kumar, S.; Wang, X.; Agrawal, N. J.; Trout, B. L.; Singh, S. K. Computational methods to predict therapeutic protein aggregation Methods Mol. Biol. 2012, 899, 425-51
43. Krobath, H.; Estácio, S. G.; Faisca, P. F.; Shakhnovich, E. I. Identification of a conserved aggregation-prone intermediate state in the folding pathways of Spc-SH3 amyloidogenic variants J. Mol. Biol. 2012, 422 (5) 705-22
44. Trinh, C. H.; Smith, D. P.; Kalverda, A. P.; Phillips, S. E.; Radford, S. E. Crystal structure of monomeric human beta-2-microglobulin reveals clues to its amyloidogenic properties Proc. Natl. Acad. Sci. U.S.A. 2002, 99 (15) 9771-6
45. Presta, L. G. Engineering antibodies for therapy Curr. Pharm. Biotechnol. 2002, 3 (3) 237-56
46. Woof, J. M. Human antibody-Fc receptor interactions illuminated by crystal structures Nat. Rev. Immunol. 2004, 4 (2) 89-99